FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947254805> ?p ?o ?g. }

• W2947254805 abstract "2018 Background: VB-111 is a non-replicating adenovirus carrying a pro-apoptotic transgene for TNFR1/Fas under the control of a modified murine promoter to pre-proendothelin 1. The transgene is expressed only in angiogenic endothelial cells, and therefore VB-111 results in targeted apoptosis of neovascular vessels. The current study characterizes the quantitative radiographic results and impact on OS in phase 2 and 3 trials of recurrent glioblastoma (GBM) patients treated with VB-111 with or without bevacizumab (BV) or BV monotherapy. Methods: MRI data from a phase 2 (NCT01260506) and randomized, double arm, controlled phase 3 (GLOBE; NCT02511405) trial of VB-111 in recurrent GBM were used in current study: Arm A) VB-111 monotherapy until progression followed by combination VB-111 and bevacizumab (BV) (“Primed Combination”; Phase 2; N = 24); Arm B) VB-111 in combination with BV (“Unprimed Combination”; Phase 3; N = 124) and Arm C) BV monotherapy (“Control”; Phase 3; N = 120). Contrast enhanced T1-weighted digital subtraction was used to quantify tumor volume at all time points. Results: Baseline tumor volume was not significantly different between patient cohorts (Kruskal-Wallis; P = 0.1482; median~20mL). Continuous measures of baseline tumor volume were prognostic for OS in all treatment groups when controlling for therapy and age (Cox, P < 0.001, HR = 1.02). In patients with small tumors ( < 25mL), the “primed combination” cohort (Arm A) from the phase 2 trial had a significant OS advantage compared to both upfront combination of VB-111 and BV (Arm B; P = 0.0094, HR = 0.5328; median OS = 7mo vs. 15mo) as well as BV alone (Arm C; P = 0.0248, HR = 0.5776; median OS = 8.5mo vs. 15mo). Patients with a radiographic response ( > 65% reduction) had a significant survival difference from non-responders when controlling for age, baseline tumor volume, and treatment arm ( P = 0.0014, HR = 0.5822). Notably, in responders to VB-111 monotherapy or combination therapy after priming with VB-111 exhibited characteristic, expansive areas of necrosis in areas of initial disease. Conclusions: Small recurrent tumors have a significant OS advantage when “priming” with VB-111 monotherapy prior to combination VB-111 and BV at recurrence. Patients responding to VB-111 exhibit specific imaging characteristics related to the drug mechanism of action. Clinical trial information: NCT02511405; NCT01260506." @default.
• W2947254805 created "2019-06-07" @default.
• W2947254805 creator A5021656597 @default.
• W2947254805 creator A5024208131 @default.
• W2947254805 creator A5025351354 @default.
• W2947254805 creator A5030410351 @default.
• W2947254805 creator A5057258539 @default.
• W2947254805 creator A5057321814 @default.
• W2947254805 creator A5062486524 @default.
• W2947254805 creator A5063511816 @default.
• W2947254805 creator A5065625958 @default.
• W2947254805 creator A5067837083 @default.
• W2947254805 creator A5075176331 @default.
• W2947254805 creator A5079645349 @default.
• W2947254805 creator A5083922162 @default.
• W2947254805 creator A5084168615 @default.
• W2947254805 creator A5085608792 @default.
• W2947254805 creator A5090305344 @default.
• W2947254805 date "2019-05-20" @default.
• W2947254805 modified "2023-10-04" @default.
• W2947254805 title "Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy." @default.
• W2947254805 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.2018" @default.
• W2947254805 hasPublicationYear "2019" @default.
• W2947254805 type Work @default.
• W2947254805 sameAs 2947254805 @default.
• W2947254805 citedByCount "1" @default.
• W2947254805 countsByYear W29472548052021 @default.
• W2947254805 crossrefType "journal-article" @default.
• W2947254805 hasAuthorship W2947254805A5021656597 @default.
• W2947254805 hasAuthorship W2947254805A5024208131 @default.
• W2947254805 hasAuthorship W2947254805A5025351354 @default.
• W2947254805 hasAuthorship W2947254805A5030410351 @default.
• W2947254805 hasAuthorship W2947254805A5057258539 @default.
• W2947254805 hasAuthorship W2947254805A5057321814 @default.
• W2947254805 hasAuthorship W2947254805A5062486524 @default.
• W2947254805 hasAuthorship W2947254805A5063511816 @default.
• W2947254805 hasAuthorship W2947254805A5065625958 @default.
• W2947254805 hasAuthorship W2947254805A5067837083 @default.
• W2947254805 hasAuthorship W2947254805A5075176331 @default.
• W2947254805 hasAuthorship W2947254805A5079645349 @default.
• W2947254805 hasAuthorship W2947254805A5083922162 @default.
• W2947254805 hasAuthorship W2947254805A5084168615 @default.
• W2947254805 hasAuthorship W2947254805A5085608792 @default.
• W2947254805 hasAuthorship W2947254805A5090305344 @default.
• W2947254805 hasConcept C126322002 @default.
• W2947254805 hasConcept C141071460 @default.
• W2947254805 hasConcept C143998085 @default.
• W2947254805 hasConcept C2776194525 @default.
• W2947254805 hasConcept C2776694085 @default.
• W2947254805 hasConcept C2777802072 @default.
• W2947254805 hasConcept C2989005 @default.
• W2947254805 hasConcept C502942594 @default.
• W2947254805 hasConcept C71924100 @default.
• W2947254805 hasConceptScore W2947254805C126322002 @default.
• W2947254805 hasConceptScore W2947254805C141071460 @default.
• W2947254805 hasConceptScore W2947254805C143998085 @default.
• W2947254805 hasConceptScore W2947254805C2776194525 @default.
• W2947254805 hasConceptScore W2947254805C2776694085 @default.
• W2947254805 hasConceptScore W2947254805C2777802072 @default.
• W2947254805 hasConceptScore W2947254805C2989005 @default.
• W2947254805 hasConceptScore W2947254805C502942594 @default.
• W2947254805 hasConceptScore W2947254805C71924100 @default.
• W2947254805 hasLocation W29472548051 @default.
• W2947254805 hasOpenAccess W2947254805 @default.
• W2947254805 hasPrimaryLocation W29472548051 @default.
• W2947254805 hasRelatedWork W1977196375 @default.
• W2947254805 hasRelatedWork W2079336916 @default.
• W2947254805 hasRelatedWork W2104392119 @default.
• W2947254805 hasRelatedWork W2121427407 @default.
• W2947254805 hasRelatedWork W2123464802 @default.
• W2947254805 hasRelatedWork W2158106887 @default.
• W2947254805 hasRelatedWork W2247406157 @default.
• W2947254805 hasRelatedWork W2318453474 @default.
• W2947254805 hasRelatedWork W2510906802 @default.
• W2947254805 hasRelatedWork W2528647848 @default.
• W2947254805 hasRelatedWork W2556659384 @default.
• W2947254805 hasRelatedWork W2591567047 @default.
• W2947254805 hasRelatedWork W2627165413 @default.
• W2947254805 hasRelatedWork W2728127642 @default.
• W2947254805 hasRelatedWork W2735595018 @default.
• W2947254805 hasRelatedWork W2747395148 @default.
• W2947254805 hasRelatedWork W2969980725 @default.
• W2947254805 hasRelatedWork W2986353227 @default.
• W2947254805 hasRelatedWork W2995556690 @default.
• W2947254805 hasRelatedWork W3014679692 @default.
• W2947254805 isParatext "false" @default.
• W2947254805 isRetracted "false" @default.
• W2947254805 magId "2947254805" @default.
• W2947254805 workType "article" @default.